Open $321.41
Day Range 318.29 - 324.52
52 Week Range 223.25 - 468.55
Market Cap $48.55B
Shares Outstanding 150.55M
Public Float 150.27M
Beta 0.82
Rev. per Employee $1.358M
P/E Ratio 16.94
EPS $19.06
Yield N/A
Dividend N/A
Ex-Dividend Date N/A
Short Interest 1.92M 06/30/21
% of Float Shorted 1.28%
Average Volume 1.99M

5 Day	-8.27%
1 Month	-13.16%
3 Month	19.68%
YTD	31.90%
1 Year	15.01%

Sell
Under
Hold
Over
Buy

Number of Ratings 32 Full Ratings

MarketWatch
Dow Jones

Biogen Research Head Defends Alzheimer's Drug

Jul. 22, 2021 at 7:40 a.m. ET

Biogen shares up 1.6% premarket

Jul. 22, 2021 at 7:32 a.m. ET by Ciara Linnane

Biogen Posts 2Q Sales, Earnings Declines on Lower Multiple-Sclerosis Drug Revenue

Jul. 22, 2021 at 7:31 a.m. ET

Biogen now sees full-year revenue $10.65 bln to $10.85 bln vs. prior $10.45 bln to $10.75 bln

Jul. 22, 2021 at 7:25 a.m. ET by Ciara Linnane

Biogen now sees full-year adj. EPS $17.50 to $19.00, unchanged vs. prior guidance

Jul. 22, 2021 at 7:24 a.m. ET by Ciara Linnane

Biogen Q2 biosimilars revenue up 18% to $202 mln

Jul. 22, 2021 at 7:23 a.m. ET by Ciara Linnane

Biogen Q2 Aduhelm revenue $2 mln

Jul. 22, 2021 at 7:23 a.m. ET by Ciara Linnane

Biogen Q2 Spinraza revenue up 1% at $500 mln

Jul. 22, 2021 at 7:23 a.m. ET by Ciara Linnane

Biogen Q2 MS revenue fell 24% to $1.786 bln

Jul. 22, 2021 at 7:22 a.m. ET by Ciara Linnane

Biogen Q2 adj. EPS $5.68

Jul. 22, 2021 at 7:22 a.m. ET by Ciara Linnane

Biogen Q2 FactSet EPS consensus $4.55; revenue $2.609 bln

Jul. 22, 2021 at 7:20 a.m. ET by Ciara Linnane

Biogen Q2 revenue $2.775 bln vs. $3.681 bln a year ago

Jul. 22, 2021 at 7:20 a.m. ET by Ciara Linnane

Biogen Q2 EPS $2.99 vs. $9.59 a year ago

Jul. 22, 2021 at 7:19 a.m. ET by Ciara Linnane

Biogen Inc. stock rises Wednesday, still underperforms market

Jul. 21, 2021 at 4:40 p.m. ET by MarketWatch Automation

Biogen Inc. stock falls Tuesday, underperforms market

Jul. 20, 2021 at 4:40 p.m. ET by MarketWatch Automation

Biogen Inc. stock falls Monday, still outperforms market

Jul. 19, 2021 at 4:40 p.m. ET by MarketWatch Automation

Barron's

Biogen Is Still a Buy Despite Alzheimer’s Drug Concerns, Analyst Says

Jul. 19, 2021 at 10:19 a.m. ET by Barron's

Biogen Inc. stock underperforms Friday when compared to competitors

Jul. 16, 2021 at 4:40 p.m. ET by MarketWatch Automation

Cleveland Clinic, Mount Sinai and Providence won’t give Biogen’s new Alzheimer’s drug

Jul. 16, 2021 at 10:00 a.m. ET

Barron's

Moderna Is Joining the S&P 500. What It Means for the Stock.

Jul. 16, 2021 at 7:45 a.m. ET

No Headlines Available

Other News
Press Releases

2 High-Risk, High-Reward Stocks That Could Go to the Moon

Jul. 22, 2021 at 6:52 a.m. ET on Motley Fool

3 Surprising Stocks That Have Crushed the Market so Far This Year

Jul. 22, 2021 at 5:55 a.m. ET on Motley Fool

Here's Why Cassava Sciences Is Surging Today

Jul. 21, 2021 at 3:39 p.m. ET on Motley Fool

2 Top Biotech Stocks to Buy Right Now

Jul. 21, 2021 at 7:18 a.m. ET on Motley Fool

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Biomea Fusion (BMEA)

Jul. 20, 2021 at 8:25 a.m. ET on TipRanks.com

Why Is Cassava Sciences Stock Soaring in 2021?

Jul. 20, 2021 at 8:12 a.m. ET on Motley Fool

Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

Jul. 20, 2021 at 7:38 a.m. ET on Zacks.com

Is It Too Late to Buy Biogen Stock?

Jul. 19, 2021 at 10:47 a.m. ET on Motley Fool

4 Large-Cap Healthcare Stocks You'll Want on Your Radar for the Second Half of 2021

Jul. 18, 2021 at 9:01 a.m. ET on Motley Fool

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Jul. 16, 2021 at 5:50 p.m. ET on Zacks.com

FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote

Jul. 16, 2021 at 9:17 a.m. ET on Zacks.com

Better Biotech Stock: Biogen vs. Annovis Bio

Jul. 16, 2021 at 7:38 a.m. ET on Motley Fool

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?

Jul. 15, 2021 at 3:01 p.m. ET on Zacks.com

Biotech Stock Roundup: BIIB & PRTA Provide Updates, CLDX Up on Positive Data & More

Jul. 14, 2021 at 3:21 p.m. ET on Zacks.com

Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs

Jul. 14, 2021 at 9:55 a.m. ET on Zacks.com

Lilly (LLY) Stock Riding on Pipeline Developments This Year

Jul. 14, 2021 at 8:19 a.m. ET on Zacks.com

Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk

Jul. 13, 2021 at 12:22 p.m. ET on Zacks.com

Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug

Jul. 13, 2021 at 10:21 a.m. ET on Zacks.com

Why the CDC and FDA Just Slapped Down Pfizer and Moderna

Jul. 13, 2021 at 5:52 a.m. ET on Motley Fool

Biogen Inks Deal with InnoCare on Orelabrutinib

Jul. 13, 2021 at 4:07 a.m. ET on TipRanks.com

No Headlines Available

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Name	Chg %	Market Cap
Sangamo Therapeutics Inc.	2.06%	$1.46B
Johnson & Johnson	0.62%	$443.6B
Sanofi ADR	0.19%	$128.31B
AbbVie Inc.	0.81%	$204.97B
Pfizer Inc.	-0.07%	$229.79B
Bio-Rad Laboratories Inc. Cl A	-0.80%	$19.96B
Acorda Therapeutics Inc.	6.13%	$35.58M
Amgen Inc.	-0.83%	$141.85B
Gilead Sciences Inc.	-1.08%	$86.74B

Competitor Data Provided By